EVENTS · SEPN
PEERS
EARNINGS
Septerna shares rose after the company announced it selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease, backed by new preclinical data presented at a medical meeting
| Series | 1W | 1M |
|---|---|---|
| SEPN | +8.2% | +34.2% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 73 | 98 |
| Series | 1W | 1M |
|---|---|---|
| SEPN | +8.2% | +34.2% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 73 | 98 |
